A recent study has found that dronabinol, a synthetic version of THC (the primary psychoactive component in cannabis), ...

Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

An FDA-approved synthetic version of THC (the main ingredient in cannabis) reduces agitation in patients with Alzheimer's ...

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show ...

Now, for the first time, a new group of drugs called monoclonal antibodies have been shown to slow down the decline in thinking and memory in Alzheimer’s patients, the most common form of dementia ...

Anxiety and depression are significant risk factors for AD, and conversely, AD increases the likelihood of developing these psychiatric conditions. A systematic review of 14,760 studies showed ...

Cognitive decline may increase an older person's risk for a fall, while the trauma that follows a fall may also speed up ...

A synthetic form of the active ingredient in cannabis helps reduce agitation in people with Alzheimer's, new research shows.

A synthetic form of the active ingredient in cannabis helps reduce agitation in people with Alzheimer's, new research shows.